OpenEvidence, a platform likened to ChatGPT for the healthcare sector, has successfully secured $200 million in funding, elevating its valuation to $6 billion, according to a report by The New York Times. This investment follows a previous round of $210 million just three months ago, during which the startup was valued at $3.5 billion, showcasing the growing demand for AI technologies tailored to the medical field.
### Key Features and Growth Trajectory
OpenEvidence leverages a vast array of medical literature, including prestigious publications like JAMA and the New England Journal of Medicine, to provide healthcare professionals with rapid access to crucial information for patient treatment. The tool is available at no charge to verified medical practitioners and is supported through advertising revenue.
The company has experienced significant growth since its inception in 2022, with clinical consultations nearly doubling to 15 million per month since July. This surge highlights the platform’s increasing adoption among healthcare providers.
### Investor Interest
This funding round was spearheaded by Google Ventures, with notable contributions from industry giants such as Sequoia Capital, Kleiner Perkins, Blackstone, Thrive Capital, Coatue Management, Bond, and Craft. The strong investor backing reflects the confidence in OpenEvidence’s potential to revolutionize patient care through AI integration in medicine.
